{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:54:56Z","timestamp":1758279296409},"reference-count":50,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To estimate budget impact of adopting lesinurad as add-on to allopurinol for urate-lowering therapy in gout.\n            <jats:bold>Methods:<\/jats:bold>\n            A budget impact model was developed for a US payer perspective, using a Markov model to estimate costs, survival and discontinuation in a one-million-member health plan. The population included patients failing first-line gout therapy, followed for 5\u00a0years.\n            <jats:bold>Results:<\/jats:bold>\n            Incremental costs of adding lesinurad versus no lesinurad were US$241,907 and US$1,098,220 in first and fifth years, respectively. Cumulative 5-year incremental cost was US$3,633,440. Estimated incremental mean cost per treated patient with gout per year was US$112. The mean per-member per-month cost increased by US$0.06.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Initiating lesinurad would result in an incremental per-member per-month cost of US$0.06 over 5\u00a0years.\n          <\/jats:p>","DOI":"10.2217\/cer-2017-0103","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T13:54:26Z","timestamp":1527170066000},"page":"807-816","source":"Crossref","is-referenced-by-count":3,"title":["Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective"],"prefix":"10.57264","volume":"7","author":[{"given":"Robert W","family":"Klein","sequence":"first","affiliation":[{"name":"Medical Decision Modeling, Inc., 3500 DePauw Blvd #1037, Indianapolis, IN 46268, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaum","family":"Kabadi","sequence":"additional","affiliation":[{"name":"AstraZeneca LP, 101 Orchard Ridge Drive, Gaithersburg, MD 20878, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank N","family":"Cinfio","sequence":"additional","affiliation":[{"name":"Medical Decision Modeling, Inc., 201 N. Illinois #1175, Indianapolis, IN 46204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Bly","sequence":"additional","affiliation":[{"name":"Medical Decision Modeling, Inc., 201 N. Illinois #1175, Indianapolis, IN 46204, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas CA","family":"Taylor","sequence":"additional","affiliation":[{"name":"Ironwood Pharmaceuticals, 301 Binney Street, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A","family":"Szymanski","sequence":"additional","affiliation":[{"name":"AstraZeneca, 101 Orchard Ridge Drive, Gaithersburg, MD 20878, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"10","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu Y","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 63(10), 3136\u20133141 (2011).","journal-title":"Arthritis Rheum."},{"issue":"9","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/annrheumdis-2013-204657","article-title":"Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout","volume":"73","author":"Chhana A","year":"2014","unstructured":"Chhana A, Callon KE, Dray M Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout. Ann. Rheum. Dis. 73(9), 1737\u20131741 (2014).","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/ard.2008.094201","article-title":"Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography","volume":"68","author":"Dalbeth N","year":"2009","unstructured":"Dalbeth N, Clark B, Gregory K Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann. Rheum. Dis. 68(8), 1290\u20131295 (2009).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/annrheumdis-2013-204273","article-title":"Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study","volume":"74","author":"Dalbeth N","year":"2015","unstructured":"Dalbeth N, Aati O, Kalluru R Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann. Rheum. Dis. 74(6), 1030\u20131036 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo CF","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. 74(4), 661\u2013667 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"e_1_3_6_8_2","first-page":"ii2","article-title":"New insights into the epidemiology of gout","volume":"48","author":"Doherty M","year":"2009","unstructured":"Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 48(Suppl. 2), ii2\u2013ii8 (2009).","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJM197906283002604","article-title":"Hyperuricemia and gout. Classification, complications and management","volume":"300","author":"Boss GR","year":"1979","unstructured":"Boss GR, Seegmiller JE. Hyperuricemia and gout. Classification, complications and management. N. Engl. J. Med. 300(26), 1459\u20131468 (1979).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3899\/jrheum.141542","article-title":"Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study","volume":"42","author":"Chen JH","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J. Rheumatol. 42(9), 1694\u20131701 (2015).","journal-title":"J. Rheumatol."},{"issue":"11","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a Mendelian randomization study","volume":"26","author":"Kleber ME","year":"2015","unstructured":"Kleber ME, Delgado G, Grammer TB Uric acid and cardiovascular events: a Mendelian randomization study. J. Am. Soc. Nephrol. 26(11), 2831\u20132838 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"14","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen LK","year":"2004","unstructured":"Niskanen LK, Laaksonen DE, Nyyssonen K Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 164(14), 1546\u20131551 (2004).","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"Zhao G","year":"2013","unstructured":"Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 231(1), 61\u201368 (2013).","journal-title":"Atherosclerosis"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley MJ","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res. Ther. 17, 90 (2015).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz F","year":"2014","unstructured":"Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73(1), 177\u2013182 (2014).","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/qjmed\/hct083","article-title":"Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality","volume":"106","author":"Stack AG","year":"2013","unstructured":"Stack AG, Hanley A, Casserly LF Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106(7), 647\u2013658 (2013).","journal-title":"QJM"},{"key":"e_1_3_6_17_2","volume-title":"The Burden Of Musculoskeletal Diseases In The United States (3rd Ed.)","author":"The United States Bone and Joint Initiative","year":"2014","unstructured":"The United States Bone and Joint Initiative. Chapter 4: Arthritis. In: The Burden Of Musculoskeletal Diseases In The United States (3rd Ed.). IL, USA (2014)."},{"issue":"1","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semarthrit.2015.02.004","article-title":"The economic burden of gout: A systematic review","volume":"45","author":"Rai SK","year":"2015","unstructured":"Rai SK, Burns LC, De Vera MA, Haji A, Giustini D, Choi HK. The economic burden of gout: A systematic review. Semin. Arthritis Rheum. 45(1), 75\u201380 (2015).","journal-title":"Semin. Arthritis Rheum."},{"issue":"10","key":"e_1_3_6_19_2","first-page":"S888","article-title":"Annual medical care expenditures among US adults with gout, 2005\u20132011","volume":"66","author":"Cisternas MG","year":"2014","unstructured":"Cisternas MG, Murphy LB, Pasta DJ, Yelin EH, Helmick CG. Annual medical care expenditures among US adults with gout, 2005\u20132011. Arthritis Rheum. 66(S10), S888\u2013S888 (2014).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","article-title":"A revised estimate of the burden of illness of gout","volume":"75","author":"Wertheimer A","year":"2013","unstructured":"Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr. Ther. Res. Clin. Exp. 75, 1\u20134 (2013).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"e_1_3_6_21_2","first-page":"11","volume-title":"ACR\/ARHP Annual Meeting.","author":"Kabadi S","year":"2016","unstructured":"Kabadi S, Myers J, Bly C. Health economics of uncontrolled gout in the United States: a systematic literature review. Presented at: ACR\/ARHP Annual Meeting. Washington, DC, USA, 11\u201316 November 2016."},{"issue":"11","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","article-title":"Health-related quality of life in gout: a systematic review","volume":"52","author":"Chandratre P","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford) 52(11), 2031\u20132040 (2013).","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna D","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64(10), 1431\u20131446 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"e_1_3_6_24_2","first-page":"145","article-title":"New and improved strategies for the treatment of gout","volume":"3","author":"Dubchak N","year":"2010","unstructured":"Dubchak N, Falasca GF. New and improved strategies for the treatment of gout. Int. J. Nephrol. Renovasc. Dis. 3, 145\u2013166 (2010).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"e_1_3_6_25_2","unstructured":"Allopurinol (2015). https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Allopurinol%20100mg%20_%20300mg%20tablets%20PIL-2164436-06112015093715-635823994423965000.pdf"},{"key":"e_1_3_6_26_2","unstructured":"Uloric (2013). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021856s011lbl.pdf"},{"issue":"13","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White WB","year":"2018","unstructured":"White WB, Saag KG, Becker MA Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378(13), 1200\u20131210 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD)","volume":"44","author":"Mikuls TR","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44(8), 1038\u20131042 (2005).","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2011.05.010","article-title":"Treatment adherence in patients with gout","volume":"78","author":"Reach G","year":"2011","unstructured":"Reach G. Treatment adherence in patients with gout. Joint Bone Spine 78(5), 456\u2013459 (2011).","journal-title":"Joint Bone Spine"},{"issue":"23","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker MA","year":"2005","unstructured":"Becker MA, Schumacher HR, Jr., Wortmann RL Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353(23), 2450\u20132461 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker MA","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12(2), R63 (2010).","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher HR","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59(11), 1540\u20131548 (2008).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_6_33_2","unstructured":"US Food and Drug Administration. Allopurinol drug details: FDA approved drug products. (2017). www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=203154"},{"issue":"2","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","article-title":"We can make gout management more successful now","volume":"20","author":"Becker MA","year":"2008","unstructured":"Becker MA, Chohan S. We can make gout management more successful now. Curr. Opin. Rheumatol. 20(2), 167\u2013172 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"12","key":"e_1_3_6_35_2","first-page":"831","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer BL","year":"2014","unstructured":"Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. Am. Fam. Physician 90(12), 831\u2013836 (2014).","journal-title":"Am. Fam. Physician"},{"issue":"1","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner J","year":"2016","unstructured":"Miner J, Tan PK, Hyndman D Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res. Ther. 18(1), 214 (2016).","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin T","year":"2016","unstructured":"Bardin T, Keenan RT, Khanna PP Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis. 76(5), 811\u2013820 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag KG","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 69(1), 203\u2013212 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_6_39_2","unstructured":"National Institute for Health and Care Excellence. Lesinurad for treating chronic hyperuricaemia in people with gout. Technology appraisal guidance [TA506] (2018). www.nice.org.uk\/guidance\/ta506"},{"issue":"4","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.22469","article-title":"Gout, urate-lowering therapy, and uric acid levels among adults in the United States","volume":"67","author":"Juraschek SP","year":"2015","unstructured":"Juraschek SP, Kovell LC, Miller ER, Iii., Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res. (Hoboken) 67(4), 588\u2013592 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"6","key":"e_1_3_6_41_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker MA","year":"2009","unstructured":"Becker MA, Schumacher HR, Macdonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J. Rheumatol. 36(6), 1273\u20131282 (2009).","journal-title":"J. Rheumatol."},{"issue":"10","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna D","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken) 64(10), 1447\u20131461 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"2","key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker MA","year":"2015","unstructured":"Becker MA, Fitz-Patrick D, Choi HK An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin. Arthritis Rheum. 45(2), 174\u2013183 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"e_1_3_6_44_2","author":"Truven Health Analytics. RED BOOK Online\u00ae","year":"2017","unstructured":"Truven Health Analytics. RED BOOK Online\u00ae. Micromedex Solutions (2017).","journal-title":"Micromedex Solutions"},{"key":"e_1_3_6_45_2","unstructured":"US Bureau of Labor Statistics. Consumer Price Index (CPI) all urban consumers. (2016). www.bls.gov\/news.release\/cpi.t01.htm"},{"issue":"4","key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz F","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47(4), 356\u2013360 (2002).","journal-title":"Arthritis Rheum."},{"issue":"6","key":"e_1_3_6_47_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/00000441-196712000-00019","article-title":"Principles of current management of primary gout","volume":"254","author":"Yu TF","year":"1967","unstructured":"Yu TF, Gutman AB. Principles of current management of primary gout. Am. J. Med. Sci. 254(6), 893\u2013907 (1967).","journal-title":"Am. J. Med. Sci."},{"issue":"7","key":"e_1_3_6_48_2","first-page":"1","article-title":"United States life tables, 2010","volume":"63","author":"Arias E","year":"2014","unstructured":"Arias E. United States life tables, 2010. Natl Vital Stat. Rep. 63(7), 1\u201363 (2014).","journal-title":"Natl Vital Stat. Rep."},{"key":"e_1_3_6_49_2","unstructured":"US Census Bureau. Current population survey annual social and economic supplement. (2013). www.census.gov\/programs-surveys\/saipe\/guidance\/model-input-data\/cpsasec.html"},{"key":"e_1_3_6_50_2","first-page":"42","volume-title":"Trendwatch Chartbook 2016.","author":"Avalere Health Llc","year":"2016","unstructured":"Avalere Health Llc. Aggregate hospital payment-to-cost ratios for private payers, Medicare and Medicaid, 1994\u20132014. In: Trendwatch Chartbook 2016. American Hospital Association, Washington, DC, USA, 42\u201342 (2016)."},{"key":"e_1_3_6_51_2","unstructured":"Centers for Medicare and Medicaid Services. Physician fee schedule search (2017). www.cms.gov\/apps\/physician-fee-schedule\/license-agreement.aspx"},{"issue":"11","key":"e_1_3_6_52_2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kes183","article-title":"Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks","volume":"51","author":"Saseen JJ","year":"2012","unstructured":"Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford) 51(11), 2004\u20132012 (2012).","journal-title":"Rheumatology (Oxford)"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:30Z","timestamp":1679231730000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.2217\/cer-2017-0103"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0103","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}